http://www.fpnotebook.com/
Hydroxyurea
- Mechanism
- Increases production of fetal Hemoglobin (HbF)
- Indications
- Indicated for 3 or more crises per year, over age 18
- Monitoring
- Baseline
- Follow-up labs (periodically and with dose change)
- Efficacy
- Reduces Sickle Cell Crisis by 50%
- Reduces Sickle Cell Anemia mortality
hydroxyurea (C0020402) | |
|---|---|
| Definition (MSH) | An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. |
| Definition (CSP) | ribonucleotide reductase inhibitor which thereby lowers intracellular dNTP pools and slows DNA replication and repair; used as antineoplastic, cell devision inhibitor, and possible chemotherapy for sickle cell anemia. |
| Definition (NCI) | An anticancer drug that belongs to the family of drugs called antimetabolites. |
| Definition (PDQ) | A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40685&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40685&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C560" NCI Thesaurus) |
| Definition (NCI) | A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D006918 |
| English | HU, HYD, Hydroxycarbamid, Hydroxycarbamide, hydroxyurea, HYDROXYUREA PREPARATION |
| Spanish | hidroxiurea |
| Parent Concepts | Antineoplastic Agents (C0003392), sickling inhibitor (C0597450), Urea (C0041942), Antimetabolites (C0003376), Ribonucleotide Reductase Inhibitors (C1373035), Antimetabolites, Antineoplastic (C0003377), Drug allergen (C1320237) |
| Sources | CSP, MSH, MTH, MTHSPL, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
